EZH2 and ovarian carcinoma: Following further investigation, the team found that EZH2 inhibitors increased the expression of MAD2L2 and rendered HR‐proficient epithelial ovarian cancer (EOC) sensitive to poly (adenosine diphosphate‐ribose) polymerase (PARP) inhibitors, dependent on CARM1.